Kexing Pharmaceutical and Liankang Group reached a strategic cooperation to jointly expand the overseas market for Tetriparpeptides.

Recently, Kexing Pharmaceuticals signed a strategic cooperation agreement with Linkang Group and reached an exclusive authorization for the commercialization of Teriparatide injections in six overseas countries including Saudi Arabia and Egypt through its subsidiary Beijing Bokang Health Gene Technology Co., Ltd. The signing ceremony was held in Zhangqiu, Jinan. Teriparatide, as a bone formation promoting agent and anti-osteoporosis drug, can effectively improve bone microstructure.